![](/images/graphics-bg.png)
Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis
Joint Authors
Shi, Ke
Li, Yuxin
Huang, Yunyi
Wang, Xiaojing
Hou, Jie
Hu, Ying
Liu, Yao
Wang, Xianbo
Ran, Chongping
Zhang, Qun
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-29
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aim.
Fuzhenghuayu (FZHY) capsule can inhibit the progression of cirrhosis.
This study explored whether FZHY can reduce the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B-caused cirrhosis (HBC) undergoing antiviral therapy.
Methods.
A retrospective review of 842 patients with HBC between 2011 and 2015 was performed, including 270 treated with FZHY combined with nucleos (t) ide analogues (NAs) and 572 with NAs alone.
The incidence of HCC was compared between the FZHY (n = 259) and control (n = 259) groups using 1 : 1 propensity score (PS) matching.
The incidence of HCC in patients with HBC with different Child-Turcotte-Pugh (CTP) classifications and Toronto HCC risk index (THRI) scores was analyzed using Kaplan–Meier curves.
Results.
The 5-year cumulative incidence of HCC before and after PS matching was 151 (17.9%) and 86 (16.6%), respectively.
In PS-matched samples, the multivariate Cox proportional-hazards model indicated that the FZHY group demonstrated a significantly lower risk for HCC than the control group (adjusted hazard ratio [aHR] = 0.32, 95% CI 0.19–0.53 P<0.001).
The risk of HCC diminished with increased duration of FZHY use.
The stratified analysis revealed that the FZHY group, regardless of CTP classification, benefited significantly from FZHY therapy.
Patients in the medium- and high-THRI risk groups were the dominant population for FZHY.
Conclusions.
FZHY combined with NAs was associated with a significantly lower risk of HCC than NAs alone in patients with HBC, which supports the integration of FZHY with antiviral treatment into clinical practice.
American Psychological Association (APA)
Shi, Ke& Liu, Yao& Wang, Xiaojing& Li, Yuxin& Zhang, Qun& Hu, Ying…[et al.]. 2020. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1158012
Modern Language Association (MLA)
Shi, Ke…[et al.]. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-9.
https://search.emarefa.net/detail/BIM-1158012
American Medical Association (AMA)
Shi, Ke& Liu, Yao& Wang, Xiaojing& Li, Yuxin& Zhang, Qun& Hu, Ying…[et al.]. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1158012
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1158012